Natália F Mendes1,2, Carlos P Jara1,2, Eli Mansour3, Eliana P Araújo1,2, Licio A Velloso4,5. 1. School of Nursing, State University of Campinas, Campinas, Brazil. 2. Laboratory of Cell Signaling, Obesity and Comorbidities Research Center, State University of Campinas, Rua Carl Von Lineaus s/n, Instituto de Biologia, Bloco Z. Campus Universitário Zeferino Vaz, Barão Geraldo, Campinas, SP, 13083-864, Brazil. 3. Clinical Immunology and Allergy, Department of Internal Medicine, State University of Campinas, Campinas, Brazil. 4. Laboratory of Cell Signaling, Obesity and Comorbidities Research Center, State University of Campinas, Rua Carl Von Lineaus s/n, Instituto de Biologia, Bloco Z. Campus Universitário Zeferino Vaz, Barão Geraldo, Campinas, SP, 13083-864, Brazil. lavellos@unicamp.br. 5. Clinical Immunology and Allergy, Department of Internal Medicine, State University of Campinas, Campinas, Brazil. lavellos@unicamp.br.
Abstract
BACKGROUND: Severe coronavirus disease-19 (COVID-19) presents with progressive dyspnea, which results from acute lung inflammatory edema leading to hypoxia. As with other infectious diseases that affect the respiratory tract, asthma has been cited as a potential risk factor for severe COVID-19. However, conflicting results have been published over the last few months and the putative association between these two diseases is still unproven. METHODS: Here, we systematically reviewed all reports on COVID-19 published since its emergence in December 2019 to June 30, 2020, looking into the description of asthma as a premorbid condition, which could indicate its potential involvement in disease progression. RESULTS: We found 372 articles describing the underlying diseases of 161,271 patients diagnosed with COVID-19. Asthma was reported as a premorbid condition in only 2623 patients accounting for 1.6% of all patients. CONCLUSIONS: As the global prevalence of asthma is 4.4%, we conclude that either asthma is not a premorbid condition that contributes to the development of COVID-19 or clinicians and researchers are not accurately describing the premorbidities in COVID-19 patients.
BACKGROUND: Severe coronavirus disease-19 (COVID-19) presents with progressive dyspnea, which results from acute lung inflammatory edema leading to hypoxia. As with other infectious diseases that affect the respiratory tract, asthma has been cited as a potential risk factor for severe COVID-19. However, conflicting results have been published over the last few months and the putative association between these two diseases is still unproven. METHODS: Here, we systematically reviewed all reports on COVID-19 published since its emergence in December 2019 to June 30, 2020, looking into the description of asthma as a premorbid condition, which could indicate its potential involvement in disease progression. RESULTS: We found 372 articles describing the underlying diseases of 161,271 patients diagnosed with COVID-19. Asthma was reported as a premorbid condition in only 2623 patients accounting for 1.6% of all patients. CONCLUSIONS: As the global prevalence of asthma is 4.4%, we conclude that either asthma is not a premorbid condition that contributes to the development of COVID-19 or clinicians and researchers are not accurately describing the premorbidities in COVID-19patients.
Authors: Safiya Richardson; Jamie S Hirsch; Mangala Narasimhan; James M Crawford; Thomas McGinn; Karina W Davidson; Douglas P Barnaby; Lance B Becker; John D Chelico; Stuart L Cohen; Jennifer Cookingham; Kevin Coppa; Michael A Diefenbach; Andrew J Dominello; Joan Duer-Hefele; Louise Falzon; Jordan Gitlin; Negin Hajizadeh; Tiffany G Harvin; David A Hirschwerk; Eun Ji Kim; Zachary M Kozel; Lyndonna M Marrast; Jazmin N Mogavero; Gabrielle A Osorio; Michael Qiu; Theodoros P Zanos Journal: JAMA Date: 2020-05-26 Impact factor: 56.272
Authors: Brian Hutton; Georgia Salanti; Deborah M Caldwell; Anna Chaimani; Christopher H Schmid; Chris Cameron; John P A Ioannidis; Sharon Straus; Kristian Thorlund; Jeroen P Jansen; Cynthia Mulrow; Ferrán Catalá-López; Peter C Gøtzsche; Kay Dickersin; Isabelle Boutron; Douglas G Altman; David Moher Journal: Ann Intern Med Date: 2015-06-02 Impact factor: 25.391
Authors: Miguel Angel Diaz; Nelly Catalan-Caceres; Thais C Beauperthuy; Carlos Domingo; Ethel Ibañez; Carmen Morata; Alfredo De Diego Journal: J Asthma Allergy Date: 2022-06-08
Authors: Lauren E Eggert; Ziyuan He; William Collins; Alexandra S Lee; Gopal Dhondalay; Shirley Y Jiang; Jessica Fitzpatrick; Theo T Snow; Benjamin A Pinsky; Maja Artandi; Linda Barman; Rajan Puri; Richard Wittman; Neera Ahuja; Andra Blomkalns; Ruth O'Hara; Shu Cao; Manisha Desai; Sayantani B Sindher; Kari Nadeau; R Sharon Chinthrajah Journal: Allergy Date: 2021-06-19 Impact factor: 14.710
Authors: Suchitra Kamle; Bing Ma; Chuan Hua He; Bedia Akosman; Yang Zhou; Chang-Min Lee; Wafik S El-Deiry; Kelsey Huntington; Olin Liang; Jason T Machan; Min-Jong Kang; Hyeon Jun Shin; Emiko Mizoguchi; Chun Geun Lee; Jack A Elias Journal: JCI Insight Date: 2021-11-08